Skip to main content

Posts

Showing posts from March 12, 2025

#HPAI Virus in #Mammals: Lack of #Detection in #Cattle With Respiratory Tract Infections & Genetic Analysis of Sporadic #Spillover Infections in Wild Mammals in #Bavaria, Germany, 2022–23

ABSTRACT Background In 2021, the H5N1 clade 2.3.4.4b Avian Influenza Viruses (AIVs) emerged on the American continent. At the same time, a further global spread took place. Infections have been reported in avian species as well as in over 50 mammalian species in 26 countries , and often result in severe disease with notable neurological pathology . Outbreaks in dairy cattle in the United States in 2024 illustrate viral transmission at a non-traditional interface and cross-species transmission. This development raises significant global concern regarding the virus's potential for wider spread. Given that H5N1 infections in birds reached record-high levels in Germany by late 2022, it is important to investigate whether Influenza A Virus (IAV) infections were also occurring in mammals sharing habitats with wild birds. Methods and Results Selected wild and domestic mammal populations were monitored over a two-year period (from January 2022 to December 2023), which coincided with a majo...

Highly Pathogenic Avian #Influenza A(#H5N1) Virus #Stability in Irradiated Raw #Milk and #Wastewater and on #Surfaces, #USA

Abstract We measured stability of infectious influenza A(H5N1) virus in irradiated raw milk and wastewater and on surfaces . We found a relatively slow decay in milk , indicating that contaminated milk and fomites pose transmission risks . Although the risk is low, our results call for caution in milk handling and disposal from infected cattle. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/4/24-1615_article ____

#Tecovirimat is #safe but #ineffective as #treatment for clade II #mpox

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH).  The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. “This study brought us a step forward in better understanding mpox disease and potential treatment strategies,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), which sponsored and funded the trial. “We are grateful to the study team and participants for their contributions to groundbreaking research on a disease that we still do not know enough about.” Mpox is caused by a virus that spreads ...